Creative Medical Technology Holdings Inc. (CELZ)
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (94%) **Content type:** Clinical